| Literature DB >> 26996911 |
Hamed Al Qarni1, Philip Collier1, Juliette O'Keeffe1, Joseph Akunna2.
Abstract
The concentrations of 12 pharmaceutical compounds (atenolol, erythromycin, cyclophosphamide, paracetamol, bezafibrate, carbamazepine, ciprofloxacin, caffeine, clarithromycin, lidocaine, sulfamethoxazole and N-acetylsulfamethoxazol (NACS)) were investigated in the influents and effluents of two hospital wastewater treatment plants (HWWTPs) in Saudi Arabia. The majority of the target analytes were detected in the influent samples apart from bezafibrate, cyclophosphamide, and erythromycin. Caffeine and paracetamol were detected in the influent at particularly high concentrations up to 75 and 12 ug/L, respectively. High removal efficiencies of the pharmaceutical compounds were observed in both HWWTPs, with greater than 90 % removal on average. Paracetamol, sulfamethoxazole, NACS, ciprofloxacin, and caffeine were eliminated by between >95 and >99 % on average. Atenolol, carbamazepine, and clarithromycin were eliminated by >86 % on average. Of particular interest were the high removal efficiencies of carbamazepine and antibiotics that were achieved by the HWWTPs; these compounds have been reported to be relatively recalcitrant to biological treatment and are generally only partially removed. Elevated temperatures and high levels of sunlight were considered to be the main factors that enhanced the removal of these compounds.Entities:
Keywords: Activated sludge; Desert climate; Pharmaceutical compounds; Removal rates; Saudi Arabia; Temperature; Wastewater
Mesh:
Substances:
Year: 2016 PMID: 26996911 PMCID: PMC4912980 DOI: 10.1007/s11356-016-6389-7
Source DB: PubMed Journal: Environ Sci Pollut Res Int ISSN: 0944-1344 Impact factor: 4.223
Comparison of removal efficiencies of pharmaceutical compounds in various wastewater treatment processes for hospital wastewater (HWWTP) and municipal wastewater (MWWTP)
| Compound | Treatment plant type | Removal (%) | Reference |
|---|---|---|---|
| Paracetamol | HWWTP AS + disinfection (GR) | 75 | Kosma et al. ( |
| MWWTP AS + sand filter (GR) | 95.6 | Kosma et al. ( | |
| MWWTP AS + trickling filter (UK) | 94 | Kasprzyk-Hordern et al. ( | |
| MWWTP (+ industrial) AS (UK) | >99 | Kasprzyk-Hordern et al. ( | |
| HWWTP MBR (pilot scale) (CH) | >99 | Kovalova et al. ( | |
| HWWTP MBR (pilot scale) (ceramic UF) (DK) | >99 | Nielsen et al. ( | |
| Carbamazepine | HWWTP AS + disinfection (GR) | 30 | Kosma et al. ( |
| MWWTP AS + sand filter (GR) | NR | Kosma et al. ( | |
| MWWTP (+ industrial) AS (ES) | NR | Radjenović et al. ( | |
| MWWTP (+ industrial) MBRc (pilot scale) (ES) | NR | Radjenović et al. ( | |
| MWWTP (+ industrial) MBRd (pilot scale) (ES) | NR | Radjenović et al. ( | |
| HWWTP MBBR (pilot scale) (DK) | 10 | Escola Casas et al. ( | |
| MWWTP AS + trickling filter (UK | NR | Kasprzyk-Hordern et al. ( | |
| MWWTP (+ industrial) AS (UK) | 13 | Kasprzyk-Hordern et al. ( | |
| HWWTP MBR (pilot scale) (CH) | −6 ± 12 | Kovalova et al. ( | |
| HWWTP MBR (pilot scale) (ceramic UF) (DK) | 1 | Nielsen et al. ( | |
| MWWTP MBR (hollow fiber membrane) | 28 | Kim et al. ( | |
| Atenolol | MWWTP (+ industrial) AS (ES) | 61.2 ± 18.6 | Radjenović et al. ( |
| MWWTP (+ industrial) MBRc (pilot scale) (ES) | 76.7 ± 12.6 | Radjenović et al. ( | |
| MWWTP (+ industrial) MBRd (pilot scale) (ES) | 69.5 ± 12.5 | Radjenović et al. ( | |
| HWWTP MBBR (pilot scale) (DK) | 40 | Escola Casas et al. ( | |
| MWWTP AS + trickling filter (UK) | 78 | Kasprzyk-Hordern et al. ( | |
| MWWTP (+ industrial) AS (UK) | 85 | Kasprzyk-Hordern et al. ( | |
| HWWTP MBR (pilot scale) (CH) | 99 ± 1 | Kovalova et al. ( | |
| HWWTP MBR (pilot scale) (ceramic UF) (DK) | 70 | Nielsen et al. ( | |
| MWWTP MBR (hollow fiber membrane) (CAN) | 77 | Kim et al. ( | |
| Bezafibrate | MWWTP (+ industrial) AS (ES) | 80.8 ± 20.9 | Radjenović et al. ( |
| MWWTP (+ industrial) MBRc (pilot scale) (ES) | 90.3 ± 10.1 | Radjenović et al. ( | |
| MWWTP (+ industrial) MBRd (pilot scale) (ES) | 88.2 ± 15.3 | Radjenović et al. ( | |
| MWWTP AS + trickling filter (UK) | 45 | Kasprzyk-Hordern et al. ( | |
| MWWTP (+ industrial) AS (UK) | 71 | Kasprzyk-Hordern et al. ( | |
| HWWTP MBR (pilot scale) (CH) | >91 | Kovalova et al. ( | |
| Lidocaine | HWWTP MBR (pilot scale) (CH) | 56 ± 13 | Kovalova et al. ( |
| Ciprofloxacin | HWWTP MBR (pilot scale) (CH) | 51 ± 13 | Kovalova et al. ( |
| HWWTP MBR (pilot scale) (ceramic UF) (DK) | 36 | Nielsen et al. ( | |
| MWWTP MBR (hollow fiber membrane) (CAN) | 89 | Kim et al. ( | |
| Clarithromycin | HWWTP MBR (pilot scale) (CH) | 50 ± 12 | Kovalova et al. ( |
| MWWTP AS + UV (TW) | NR | Lin et al. ( | |
| MWWTP AS + chlorination (TW) | NR | Lin et al. ( | |
| MWWTP AS + chlorination (TW) | 10 | Lin et al. ( | |
| MWWTP AS + sand filer (TW) | NR | Lin et al. ( | |
| MWWTP trickling filter + chlorination (TW) | 99 | Lin et al. ( | |
| MWWTP AS + chlorination (TW) | NR | Lin et al. ( | |
| HWWTP MBR (pilot scale) (ceramic UF) (DK) | 64 | Nielsen et al. ( | |
| MWWTP MBR (hollow fiber membrane) (CAN) | NR | Kim et al. ( | |
| Sulfamethoxazole | MWWTP (+ industrial) AS (ES) | 73.8 ± 12.7 | Radjenović et al. ( |
| MWWTP (+ industrial) MBRc (pilot scale) (ES) | 80.8 ± 12.2 | Radjenović et al. ( | |
| MWWTP (+ industrial) MBRd (pilot scale) (ES) | 78.3 ± 13.9 | Radjenović et al. ( | |
| HWWTP MBBR (pilot scale) (DK) | NR | Escola Casas et al. ( | |
| MWWTP AS + trickling filter (UK) | 66 | Kasprzyk-Hordern et al. ( | |
| MWWTP (+ industrial) AS (UK) | 83 | Kasprzyk-Hordern et al. ( | |
| HWWTP MBR (pilot scale) (CH) | 7 ± 57 | Kovalova et al. ( | |
| MWWTP AS + UV (TW) | 42 | Lin et al. ( | |
| MWWTP AS + chlorination (TW) | 20 | Lin et al. ( | |
| MWWTP AS + chlorination (TW) | 59 | Lin et al. ( | |
| MWWTP AS + sand filter (TW) | 88 | Lin et al. ( | |
| MWWTP trickling filter + chlorination (TW) | 45 | Lin et al. ( | |
| MWWTP AS + chlorination (TW) | 26 | Lin et al. ( | |
| HWWTP MBR (pilot scale) (ceramic UF) (DK) | 97 | Nielsen et al. ( | |
| MWWTP MBR (hollow fiber membrane) (CAN) | 66 | Kim et al. ( | |
| Erythromycin | MWWTP (+ industrial) AS (ES) | 35.4 ± 50.5 | Radjenović et al. ( |
| MWWTP (+ industrial) MBRc (pilot scale) (ES) | 43.0 ± 51.5 | Radjenović et al. ( | |
| MWWTP (+ industrial) MBRd (pilot scale) (ES) | 25.2 ± 108.9 | Radjenović et al. ( | |
| HWWTP MBBR (pilot scale) (DK) | <20 | Escola Casas et al. ( | |
| MWWTP AS + trickling filter (UKa) | 14 | Kasprzyk-Hordern et al. ( | |
| MWWTP (+ industrial) AS (UKa) | 72 | Kasprzyk-Hordern et al. ( | |
| HWWTP MBR (pilot scale) (CHb) | <60 | Kovalova et al. ( | |
| MWWTP AS + UV (TWa) | NR | Lin et al. ( | |
| MWWTP AS + chlorination (TWa) | NR | Lin et al. ( | |
| MWWTP AS + chlorination (TWa) | 77 | Lin et al. ( | |
| MWWTP AS + sand filter (TWa) | NR | Lin et al. ( | |
| MWWTP trickling filter + chlorination (TWa) | 56 | Lin et al. ( | |
| MWWTP AS + chlorination (TWa) | NR | Lin et al. ( | |
| HWWTP MBR (pilot scale) (ceramic UF) (DK) | 37 | Nielsen et al. ( | |
| MWWTP MBR (hollow fiber membrane) (CANa) | 12 | Kim et al. ( | |
| Cyclophosphamide | HWWTP MBR (pilot scale) (CH) | <20 | Kovalova et al. ( |
| HWWTP MBR (pilot scale) (ceramic UF) (DK) | 12 | Nielsen et al. ( | |
| Caffeine | HWWTP AS + disinfection (GR) | 75 | Kosma et al. ( |
| MWWTP AS + sand filter (GR) | 89 | Kosma et al. ( | |
| MWWTP AS + UV (TW) | 99 | Lin et al. ( | |
| MWWTP AS + chlorination (TW) | >99 | Lin et al. ( | |
| MWWTP AS + chlorination (TW) | 97 | Lin et al. ( | |
| MWWTP AS + sand filter (TW) | 99 | Lin et al. ( | |
| MWWTP trickling filter + chlorination (TW) | 96 | Lin et al. ( | |
| MWWTP AS + chlorination (TW) | >99 | Lin et al. ( | |
| MWWTP MBR (hollow fiber membrane) (CAN) | 100 | Kim et al. ( |
AS activated sludge, MBR membrane bioreactor, MBBR moving bed biofilm reactor, UF ultrafiltration, NR no removal, CAN Canada, CH Switzerland, DK Denmark, ES Spain, GR Greece, TW Taiwan, UK United Kingdom
aErythromycin·H2O
bErythromycin + Eryt·H2O (30–100 %)
cFlat sheet microfiltration
dHollow fiber UF
Overview of the operational parameters at the two hospital wastewater treatment plants studied
| Parameters | HWWTP1 | HWWTP2 | ||
|---|---|---|---|---|
| Number of beds | 300 | 215 | ||
| Annual wastewater volume (m3) | 330,000 | 227,000 | ||
| Process technology | Aerobic | Aerobic | ||
| Ambient (°C) | 28 ± 7 | 28 ± 7 | ||
| pH | 7.0–7.5 | 6.8–7.5 | ||
| Influent | Effluent | Influent | Effluent | |
| COD (mg/L) | 376 | 64 | 336 | 27 |
| NH4 + (mg/L) | 22.3 | 0.3 | 19.0 | 0 |
| NO2 − (mg/L) | 0.3 | 0.6 | 0.3 | 0.3 |
| NO3 − (mg/L) | 0.2 | 0.7 | 0.4 | 2.4 |
Fig. 1Schematic of the treatment processes employed in the a hospital wastewater treatment plant 1 and b hospital wastewater treatment plant 2; (X = sampling point)
Mass spectrometry: positive ion mode, range, and limit of quantification (LOQ)
| Analyte | MS ion/transitiona | Retention time (min) | MS experiment | Linear range (ng/ml) | LOQ (ng/ml) |
|---|---|---|---|---|---|
| Atenolol | 267.1703 | 6.38 | Full scan | 0.1–500 | 5 |
| Bezafibrate | 362.11–316.1089 | 19.63 | Targeted MS2 | 0.1–500 | 0.1 |
| Carbamazepine | 237.10–194.0964 | 17.72 | Targeted MS2 | 0.25–500 | 0.25 |
| Caffeine | 195.0877 | 7.20 | Full scan | 2.5–500 | 2.5 |
| Ciprofloxacin | 332.14–288.1505 | 7.43 | Targeted MS2 | 0.25–500 | 2.5 |
| Clarithromycin | 748.48–158.1176 | 19.08 | Targeted MS2 | 0.1–250 | 0.5 |
| Cyclophosphamide | 261.03–140.0029 | 10.68 | Targeted MS2 | 0.5–500 | 1 |
| Erythromycin | 734.47–158.1176 | 14.99 | Targeted MS2 | 0.5–500 | 0.5 |
| Lidocaine | 235.1805 | 7.88 | Full scan | 1–500 | 1 |
| NACS | 296.07–134.0602 | 10.69 | Targeted MS2 | 2.5–500 | 5 |
| Paracetamol | 152.0706 | 6.80 | Full scan | 0.5–500 | 0.5 |
| Sulfamethoxazole | 254.06–108.0445 | 10.59 | Targeted MS2 | 1–500 | 1 |
aThe underlined m/z being used for quantification
Concentrations of pharmaceutical compounds in hospital wastewater treatment plants in Saudi Arabia (ng/L)a
| Class | Compound | LOQb | HWWTP1 | HWWTP1 | HWWTP2 | HWWTP2 |
|---|---|---|---|---|---|---|
| Inf. | Eff. | Inf. | Eff. | |||
| Analgesics | Paracetamol | 0.5 | 12400 ± 340 | 73 ± 11 | 12300 ± 180 | 157 ± 20 |
| Antidepressants | Carbamazepine | 0.25 | 151 ± 13 | 41 ± 1 | 73 ± 14 | n/d |
| β-blockers | Atenolol | 5.0 | 730 ± 82 | 46 ± 2 | 329 ± 28 | 55 ± 4 |
| Lipid regulators | Bezafibrate | 0.1 | n/d | n/d | n/d | n/d |
| Anesthetics | Lidocaine | 1.0 | 158 ± 12 | 114 ± 4 | 129 ± 6 | <LOQ |
| Antibiotics | Ciprofloxacin | 2.5 | 5600 ± 660 | n/d | 2180 ± 250 | n/d |
| Clarithromycin | 0.5 | 83 ± 72 | 22 ± 9 | 38 | n/d | |
| Sulfamethoxazole | 1.0 | 30 ± 7 | n/d | 132 ± 5 | n/d | |
| Erythromycin | 0.5 | n/d | n/d | n/d | n/d | |
|
| NACS | 5.0 | 1200 ± 55 | 59 ± 14 | 506 ± 21 | n/d |
| Cytostatic | Cyclophosphamide | 1.0 | n/d | n/d | n/d | n/d |
| Others | Caffeine | 2.5 | 74,800 ± 15,500,502 | n/d | 27,500 ± 2000 | n/d |
n/d not detected
aEach sample was analyzed in triplicate. Results are reported as mean ± standard deviation (n = 3)
bLimit of quantitation (substances detected but not quantifiable); n/d = not detected
Fig. 2Removal efficiencies of pharmaceutical compounds at HWWTP1 and HWWPT2 in Saudi Arabia. Results shown are mean removal (n = 3)